Journals / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 1

Therapeutic Treatment with Abdominal Adipose Mesenchymal Cells Does Not Prevent Elastase-Induced Emphysema in Rats

Pages
14–20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no statistically significantdifference between the BALF and serum MMP-9 levels between the control and treatment groups.CONCLUSION: Our findings suggest that therapeutic treatment with adipose tissue-derived MSC in rats has no effect on emphysema oron MMP9 expression, which is a known marker of emphysema.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: Emphysema and chronic bronchitis have different pathophysiologies but both are significant components of chronic obstructive lung disease (COPD).
📊
Key Findings & Data:The levels of Matrix metalloproteinase (MMP)-9 in the bronchoalveloar lavage fluid (BALF) and in serumindicate the presence of emphysema.
💡
Conclusion & Impact:There was no statistically significantdifference between the BALF and serum MMP-9 levels between the control and treatment groups.CONCLUSION: Our findings suggest that therapeutic treatment with adipose tissue-derived MSC in rats has no effect on emphysema oron MMP9 expression, which is a known marker of emphysema.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVES: Emphysema and chronic bronchitis have different pathophysiologies but both are significant components of chronic obstructive lung disease (COPD). The levels of Matrix metalloproteinase (MMP)-9 in the bronchoalveloar lavage fluid (BALF) and in serumindicate the presence of emphysema. Intratracheal administration of elastase has been used to create a rat model of emphysema. Adiposetissue-derived mesenchymal stem cells (MSC) have been postulated to prevent or reverse emphysema, however, this has not been examined in the rat model of elastase-induced emphysema.MATERIALS AND METHODS: In this study, 31 Wistar albino rats aged 6–8 weeks and weighing 250–300 g were assessed. On day 1, theanimals were treated intratracheally with 0.5 mL saline (control group, n=10), i.e., 0.5 mL saline solution containing 0.1 IU porcine pancreatic elastase (PPE) (Elastase group, n=12) or PPE plus MSC (Elastase-MSC group, n=9) was adminstered per animal. MSCs suspendedin serum were injected via the caudal vein on day 21. At least 106 cells were injected. All animals were sacrificed on day 42 and theemphysema index (EI) was calculated, along with measuring the BALF and serum MMP-9 concentrations.RESULTS: Porcine pancreatic elastase induced a significant degree of emphysema in the PPE groups as compared to the control group,which was determined by the EI index (p=0.008). This was not reversed by MSC treatment. The EI remained significantly low in comprison with the controls (p=0.001) and measured no different from the Elastase-treated animals. There was no statistically significantdifference between the BALF and serum MMP-9 levels between the control and treatment groups.CONCLUSION: Our findings suggest that therapeutic treatment with adipose tissue-derived MSC in rats has no effect on emphysema oron MMP9 expression, which is a known marker of emphysema.

🔖

Cite This Article

GÜLHAN, P. Y., EKİCİ, M. S., EKİCİ, A., NİYAZ, M., GÜLHAN, M., ERCİN, M. E., AKSOY, N. (2020). Therapeutic Treatment with Abdominal Adipose Mesenchymal Cells Does Not Prevent Elastase-Induced Emphysema in Rats. Turkish Thoracic Journal, Cilt: 21 - Sayı: 1, 14–20. https://ajindex.com/articles/417927

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD (Updated 2017). In; 2017
  2. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163(3 Pt 1):737-44. [CrossRef] 3. Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: The vascular story. Pulm Circ 2011;1:320-6. [CrossRef] 4. Cheng SL, Lin CH, Yao CL. Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science. Stem Cells Int 2017;2017:8916570. [CrossRef] 5. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28:585- 96. [CrossRef] 6. Zhen G, Liu H, Gu N, et al. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci 2008;13:3415-22. [CrossRef] 7. Liu HM, Zhen GH, Zhang ZX, et al. Effects of bone marrow mesenchymal stem cells transplantation on the apoptosis of alveolar wall cells in papain and Co60-induced pulmonary emphysema rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2008;24:210-4
  3. Wagner DE, Cardoso WV, Gilpin SE, et al. ATS Subcommittee on Stem Cells and Cell Therapies. An Official American Thoracic Society Workshop Report 2015. Stem Cells and Cell Therapies in Lung Biology and Diseases. Ann Am Thorac Soc 2016;13:S259-78. [CrossRef] 9. Osiris. Osiris Therapeutics Reports interim data for COPD stem cell study 2009. In; 2012
  4. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010;138:965-72. [CrossRef] 11. Cho RJ, Kim YS, Kim JY, et al. Human adipose-derived mesenchymal stem cell spheroids improve recovery in a Mouse model of elastase-induced emphysema. BMB Rep 2017;50:79-84. [CrossRef] 12. Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1120-8. [CrossRef] 13. Weiss DJ, Kolls JK, Ortiz LA, et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5:637-67. [CrossRef] 14. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33:145-52. [CrossRef]